• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Could Drug Research Partnership Just Shift Quantum Computing's (QUBT) Investment Narrative?

    Simply Wall St·10/24/2026 00:29:19
    Listen to the news
    • In October 2026, INmune Bio and Quantum Computing Inc. announced a collaboration that applies QCi's Dirac-3S quantum optimization, AI and traditional analytics to INmune Bio's pre clinical and clinical data for XPro, with the aim of identifying additional disease indications and refining patient targeting.
    • The partnership gives Quantum Computing Inc. its first commercial customer in pharmaceuticals and provides a real world testbed for its room temperature, low power quantum systems. It also gives INmune Bio a structured process to evaluate XPro's potential across multiple diseases.
    • The focus now turns to how Quantum Computing Inc.'s investment narrative around practical quantum systems is affected by this initial pharmaceutical collaboration.

    Scan beyond Quantum Computing and evaluate room temperature quantum and AI peers using our curated list of 55 AI infrastructure stocks for potential real world deployment stories like this one.

    Quantum Computing Investment Narrative Recap

    To own Quantum Computing, you need to believe its room temperature photonic systems and thin film lithium niobate fabs can move from small research contracts to repeatable, scaled products across computing, networking and security. The INmune Bio deal fits that story by showing a concrete pharma use case, but it is still an early stage engagement.

    The biggest near term catalyst remains evidence that pilots turn into multi year deployments that increase the US$9.8 million revenue base and improve utilization at Fab 1 and Fab 2. The main risk remains the same: operating expenses of US$10.5 million a quarter and a net loss of US$17.1 million over nine months keep cash burn in focus.

    The INmune Bio collaboration is the clearest recent proof point tied to that catalyst. It is QCi's first commercial pharmaceutical customer and directly showcases the Dirac 3S entropy quantum optimization machine on real clinical and biomedical data. That goes beyond a lab demo and places the hardware alongside a drug program with meaningful datasets.

    For you as a shareholder, the key question is execution. Does this pilot expand into broader work under the options in the agreement, or does it remain a single project that does not change revenue concentration risk around custom contracts? Until there is more disclosure on follow-on scope, the announcement is encouraging for Quantum Computing's story but not yet a company-changing contract.

    What The Quantum Computing Consensus Is Pricing In

    Analysts are effectively asking investors to underwrite a very steep ramp for Quantum Computing. Consensus models point to revenue growing at about 283% a year over the next three years, tied to the idea that photonic quantum systems and thin film lithium niobate capacity find broader commercial demand beyond one off contracts such as the INmune Bio pilot.

    On profitability, the gap is wide. The business reports an earnings loss of US$39.7 million today, while analyst forecasts point to earnings of US$1.8 million by 2029. That is an earnings swing of roughly US$41.5 million, which would also take profit margins from a deeply negative level of 916.2% to a slightly positive 0.7% over the same period.

    Those earnings assumptions sit inside a specific calendar anchor. The consensus view referenced here targets July 2029 as the point where Quantum Computing reaches US$1.8 million in earnings and a modest positive margin, with share count expected to rise about 7% a year for the next three years as the company funds expansion.

    On the top line, the same 2029 snapshot calls for US$243.4 million in revenue. That forecast, together with the US$1.8 million earnings figure for that year, underpins the analyst price target of US$18.33 and implies a P/E multiple of 3,628x those projected profits, compared with a current P/E of 44.6x on today’s loss making base.

    Quantum Computing's current analyst narrative points to forecast revenue of US$243.4 million and earnings of US$1.8 million by 2029. That profile assumes yearly revenue growth of 283% and an earnings swing of about US$41.5 million from current earnings of a US$39.7 million loss.

    Uncover why Quantum Computing's fair value indicates a 179% potential upside to its current price, which could narrow quickly.

    NasdaqCM:QUBT 1-Year Stock Price Chart
    NasdaqCM:QUBT 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate angle focuses on capacity risk rather than pharma upside. The most cautious Quantum Computing analysts were only penciling in about US$72.6 million of revenue and US$5.4 million of earnings by 2029, well below the bullish consensus. That gap shows how far opinions can spread, so explore several views as this INmune Bio collaboration beds in.

    Explore 3 other Quantum Computing fair value estimates, including one that suggests it could be worth just $10.00!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis and judgment.

    • A great starting point for your Quantum Computing research is our analysis highlighting 1 key reward that could impact your investment decision.
    • See our latest analysis for Quantum Computing. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Quantum Computing's overall financial health at a glance.

    Looking For More Investment Ideas Beyond Quantum Computing?

    Once you have a view on Quantum Computing, it often helps to compare it with other opportunities that fit different risk and quality profiles. The Simply Wall St Screener lets you do that quickly by filtering the market down to focused shortlists that match what you are actually looking for.